Pharsight

Intrarosa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629129 MILLICENT Pharmaceutical compositions
Aug, 2028

(4 years from now)

US8957054 MILLICENT Pharmaceutical compositions
Jan, 2030

(5 years from now)

US8268806 MILLICENT Pharmaceutical compositions
Mar, 2031

(6 years from now)

Intrarosa is owned by Millicent.

Intrarosa contains Prasterone.

Intrarosa has a total of 3 drug patents out of which 0 drug patents have expired.

Intrarosa was authorised for market use on 16 November, 2016.

Intrarosa is available in insert;vaginal dosage forms.

Intrarosa can be used as intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Drug patent challenges can be filed against Intrarosa from 16 November, 2020.

The generics of Intrarosa are possible to be released after 19 March, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using PRASTERONE ingredient

NCE-1 date: 16 November, 2020

Market Authorisation Date: 16 November, 2016

Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Dosage: INSERT;VAGINAL

More Information on Dosage

INTRAROSA family patents

Family Patents